These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 29309600)

  • 21. Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease.
    Bohnen NI; Kaufer DI; Hendrickson R; Ivanco LS; Lopresti B; Davis JG; Constantine G; Mathis CA; Moore RY; DeKosky ST
    Neurosci Lett; 2005 May 20-27; 380(1-2):127-32. PubMed ID: 15854764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced Hippocampal Glutamate and Posterior Cingulate N-Acetyl Aspartate in Mild Cognitive Impairment and Alzheimer's Disease Is Associated with Episodic Memory Performance and White Matter Integrity in the Cingulum: A Pilot Study.
    Wong D; Atiya S; Fogarty J; Montero-Odasso M; Pasternak SH; Brymer C; Borrie MJ; Bartha R
    J Alzheimers Dis; 2020; 73(4):1385-1405. PubMed ID: 31958093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Nexus of Cholinergic and Nerve Growth Factor Dysfunction.
    Moss DE; Perez RG
    Curr Alzheimer Res; 2021; 18(13):1010-1022. PubMed ID: 34911424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholinergic system function and cognition in mild cognitive impairment.
    Haense C; Kalbe E; Herholz K; Hohmann C; Neumaier B; Krais R; Heiss WD
    Neurobiol Aging; 2012 May; 33(5):867-77. PubMed ID: 20961662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Voxel-Based Acetylcholinesterase PET Study in Early and Late Onset Alzheimer's Disease.
    Hirano S; Shinotoh H; Shimada H; Ota T; Sato K; Tanaka N; Zhang MR; Higuchi M; Fukushi K; Irie T; Kuwabara S; Suhara T
    J Alzheimers Dis; 2018; 62(4):1539-1548. PubMed ID: 29562505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced acetylcholinesterase activity in the fusiform gyrus in adults with autism spectrum disorders.
    Suzuki K; Sugihara G; Ouchi Y; Nakamura K; Tsujii M; Futatsubashi M; Iwata Y; Tsuchiya KJ; Matsumoto K; Takebayashi K; Wakuda T; Yoshihara Y; Suda S; Kikuchi M; Takei N; Sugiyama T; Irie T; Mori N
    Arch Gen Psychiatry; 2011 Mar; 68(3):306-13. PubMed ID: 21383265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Response to Cholinesterase Inhibitor Treatment Is Related to Functional MRI Response in Alzheimer's Disease.
    Miettinen PS; Jauhiainen AM; Tarkka IM; Pihlajamäki M; Gröhn H; Niskanen E; Hänninen T; Vanninen R; Soininen H
    Dement Geriatr Cogn Disord; 2015; 40(5-6):243-55. PubMed ID: 26305064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease.
    Croteau E; Castellano CA; Fortier M; Bocti C; Fulop T; Paquet N; Cunnane SC
    Exp Gerontol; 2018 Jul; 107():18-26. PubMed ID: 28709938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain Cholinergic Function and Response to Rivastigmine in Patients With Chronic Sequels of Traumatic Brain Injury: A PET Study.
    Östberg A; Virta J; Rinne JO; Oikonen V; Luoto P; Någren K; Arponen E; Tenovuo O
    J Head Trauma Rehabil; 2018; 33(1):25-32. PubMed ID: 28060207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.
    Chételat G; Villemagne VL; Pike KE; Ellis KA; Bourgeat P; Jones G; O'Keefe GJ; Salvado O; Szoeke C; Martins RN; Ames D; Masters CL; Rowe CC;
    Brain; 2011 Mar; 134(Pt 3):798-807. PubMed ID: 21310725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
    Kadir A; Darreh-Shori T; Almkvist O; Wall A; Långström B; Nordberg A
    Psychopharmacology (Berl); 2007 May; 191(4):1005-14. PubMed ID: 17310387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease.
    Herholz K; Weisenbach S; Zündorf G; Lenz O; Schröder H; Bauer B; Kalbe E; Heiss WD
    Neuroimage; 2004 Jan; 21(1):136-43. PubMed ID: 14741650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contribution of the Cholinergic System to Verbal Memory Performance in Mild Cognitive Impairment.
    Peter J; Lahr J; Minkova L; Lauer E; Grothe MJ; Teipel S; Köstering L; Kaller CP; Heimbach B; Hüll M; Normann C; Nissen C; Reis J; Klöppel S
    J Alzheimers Dis; 2016 Jun; 53(3):991-1001. PubMed ID: 27340852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
    Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Basal Forebrain and Hippocampus as Predictors of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment - A Multicenter DTI and Volumetry Study.
    Brueggen K; Dyrba M; Barkhof F; Hausner L; Filippi M; Nestor PJ; Hauenstein K; Klöppel S; Grothe MJ; Kasper E; Teipel SJ
    J Alzheimers Dis; 2015; 48(1):197-204. PubMed ID: 26401940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.
    Modrego PJ; Pina MA; Fayed N; Díaz M
    CNS Drugs; 2006; 20(10):867-77. PubMed ID: 16999455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study.
    Kumari V; Aasen I; ffytche D; Williams SC; Sharma T
    Neuroimage; 2006 Jan; 29(2):545-56. PubMed ID: 16181792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
    Imbimbo BP
    CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.